Cytokinetics (CYTK) has announced an expanded strategic funding collaboration with Royalty Pharma totaling up to $575 million. The deal, aimed at supporting the commercial launch of Cytokinetics' heart drug aficamten and advancing its R&D pipeline, has lowered hopes of a buyout. Additionally, Cytokinetics is planning another Phase III trial for omecamtiv mecarbil, a drug that was previously thought to be sidelined. Despite the significant financial agreement, there is criticism regarding the timing of the offering, with some suggesting it should have been done months ago when the stock price was higher. The company had announced positive Phase III results in late December 2023.
$cytk dont think the financing is prohibitive to M&A prospects, esp since 1) it provides funding for non-aficamten clinical trials acquirer may not have interest in; 2) does not involve a new partner ...but yeah, Blum made big mistake and knee-jerk will hurt.…
$CYTK lol. I read the STAT about one week ago I guess. I didn't like CEO and sold afterwards. Another catastrophe avoided... https://t.co/Y6FpUEJo93
$CYTK lol. I read the STAT about one week ago I guess. I didn't like CEO and sold afterwards. https://t.co/Y6FpUEJo93
$CYTK great job management Announced positive ph3 results in late December 2023 Management kept quiet, no secondary when stock hit ATH Management quiet for five months and did a big secondary today when stock price nearly back to pre data levels Incompetence at its best
While Wall Street keeps pushing a buyout exit for Cytokinetics, the company's leadership has other plans. https://t.co/jeF5G6PKcJ
On Wall Street, hopes dimmed that Cytokinetics, a drugmaker that is expected to soon launch a promising new heart therapy called aficamten, will be acquired. https://t.co/amHxGEO910
Cytokinetics sells Royalty Pharma a share of its heart drug for up to $575 million, lowering hopes of a buyout https://t.co/XX5UJYrJcl via @elaineywchen and @matthewherper for @statnews
Maybe the most surprising thing about the $CYTK royalty financing deal and follow-on offering is not that Cytokinetics is not being imminently acquired but that the company is reviving omecamtiv with a new confirmatory Phase III trial. https://t.co/5J1Y1NE6G4
Cytokinetics $CYTK sells Royalty Pharma a share of its heart drug for up to $575 million, lowering hopes of a buyout https://t.co/3pzG81TniM via @matthewherper @elaineywchen
talk about a kick in the ole blums $cytk
we're still awaiting asia rights X) $cytk https://t.co/i1ZyjulFoe
The day before the $CYTK P3 data PR - stk closed at 45.71 - think about that... now it is at 52s - .. maybe Blum will get another nomination in a different way for the 2024 list.. Ha!
$CYTK Good. https://t.co/PFvngFEo9G
$CYTK the most biotechy, band-aid ripping, clearing event.
Well - $CYTK - Blum strikes again - though I do very much like the price here - the offering hopefully will clear the pocket - why didn't the morons do the offering at much higher prices - .. then this detail in the $RPRX agreement - omecamtiv mecarbil is not dead - Ha!
$CYTK should have raised months ago after results
$CYTK big money deal with Royalty Pharma... but no buyout. https://t.co/8erVElC5he
$CYTK offering
$CYTK Guess no buyout soon! https://t.co/BwkHp42WOb
$CYTK $RPRX Cytokinetics and Royalty Pharma Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline https://t.co/Ca2rQllYvF
$CYTK is planning another P3 for Omecamtiv!
I don’t often ask - but any pharma + biotech followers out there can help with $CYTK ? Near term (3-6m) views